Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
boceprevir + peginterferon alfa-2a + ribavirin
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**Boceprevir + peginterferon alfa-2a + ribavirin** is a triple drug regimen used for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. It combines: - **boceprevir**, a small molecule protease inhibitor that specifically targets the HCV NS3/4A serine protease, thereby preventing viral replication; - **peginterferon alfa-2a**, a pegylated type I interferon that exerts antiviral and immunomodulatory effects by binding to interferon alpha receptors, stimulating an antiviral state and activating immune cells; - **ribavirin**, a nucleoside analog that acts as a broad-spectrum antiviral, likely through mechanisms including inhibition of RNA-dependent RNA polymerase and induction of lethal mutagenesis. The regimen was historically an advance for HCV genotype 1 but is now superseded by newer therapies. Therapy typically begins with 4 weeks of peginterferon alfa-2a and ribavirin, then boceprevir is added. The combination demonstrated improved sustained virologic response rates (SVR) compared to dual therapy, but is associated with higher incidence of anemia and neutropenia[1][2][3][4].
- Brand names
- Pegasys + Copegus + Victrelis
- Other names
- triple therapy for HCV genotype 1 with boceprevirboceprevir + pegylated interferon alfa-2a + ribavirinBOC/PEG2a/RBOC + PEG-IFN-alfa-2a + RBV
02
Targets
ABCB1 (P-glycoprotein)IFNAR (Immune system modulation via type I interferon receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on boceprevir + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on boceprevir + peginterferon alfa-2a + ribavirin.